Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AngloGold Ashanti Limited (AU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs AngloGold Ashanti Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while AngloGold Ashanti Limited trades at $80.65 (market cap $41.51B). The key difference: Alnylam Pharmaceuticals, Inc. and AngloGold Ashanti Limited are close in size by market cap, and AngloGold Ashanti Limited pays a 5.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AU | |
|---|---|---|
Market Cap | $39.89B | $41.51B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $128.26 |
52-Week Low | $278.09 | $46.25 |
Enterprise Value | $38.15B | $40.64B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AngloGold Ashanti (AU) trades at $82.10, up 0.23% on the day, with a bearish technical signal but strong fundamentals. Recent Q1 2026 earnings beat expectations with EPS of $2.52 versus $2.27 forecast. The company shows robust revenue growth, with 2025 revenue at $9.89 billion and net income margin of 26.64%. A proposed share repurchase program and a $1.16 dividend for H1 2026 highlight capital returns. Analyst consensus is bullish with a $116.25 price target, though technical indicators suggest near-term resistance.
Outlook remains positive driven by gold price strength and operational efficiency, but risks include geopolitical exposure and commodity volatility. The stock offers value with a P/E of 12.06 and high ROE of 45.39%, yet bearish technical trends and recent earnings misses in Q3 and Q4 2025 warrant caution. Institutional sentiment is mixed, with 64% buy ratings but technical selling pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →
